Multidrug-resistant tuberculosis successful treatment in an infant
Main Article Content
Abstract
We report a case of multidrug-resistant tuberculosis (MDR-TB)
in a six-month infant having an initial diagnosis of pneumonia
without improvement after antibiotic use. The gastric aspirate
sample showed smear microscopy and culture positives. Her
mother had respiratory symptomatology, positive smear
(+++), bilateral cavities on chest x-ray, and a smoking habit. The
child and her mother had culture positive for Mycobacterium
tuberculosis (Mtb) and both sensitivity tests presented the
same pattern of multidrug-resistance. Treatment regimen was
composed of capreomycin, ethambutol, levofloxacin, terizidon
and pyrazinamide. The child had an excellent response, evolving
to a cure after 15 months of treatment. It is extremely important
to seek early diagnosis, the history of close contact, and prompt
establishment of the therapeutic regimen for the successful
treatment of MDR-TB in children.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
1. Ministério da saúde (BR) SVS. Manual de Recomendações para o Controle da Tuberculose no Brasil. 2a Edição. Brasília: Ministério da Saúde, https://bvsms.saude.gov.br/bvs/publicacoes/manual_ recomendacoes_controle_tuberculose_brasil_2_ed.pdf (2019).
2. WHO-World Health Organization. Global tuberculosis report 2023. World Health Organization, https://www.who.int/publications detail-redirect/9789240083851 (2023).
3. Schaaf HS, Garcia-Prats AJ. Multidrug-Resistant Tuberculosis in Children: Recent Developments in Diagnosis, Treatment and Prevention. Curr Pediatr Rep. 2016; 4: 53–62.
4. Huynh J, Marais BJ. Multidrug-resistant tuberculosis infection and disease in children: a review of new and repurposed drugs. Ther Adv Infect Dis. 2019; 6: 2049936119864737.
5. BRASIL-Ministério da Saúde. Sistema de Registro de Tratamentos Especiais de Tuberculose (SITETB) - http://sitetb.saude.gov.br (2023).
6. Seddon JA, Johnson S, Palmer M, van der Zalm MM, Lopez Varela E, Hughes J, Schaaf HS. Multidrug-resistant tuberculosis in children and adolescents: current strategies for prevention and treatment. Expert Rev Respir Med. 2021; 15: 221–237.
7. The Sentinel Project for Pediatric Drug-Resistant Tuberculosis. Management of Drug-Resistant Tuberculosis in Children: A Field Guide. 5a Edição. Boston, USA, https://sentinel-project.org/wp content/uploads/2022/04/DRTB-Field-Guide-2021_v5.1.pdf (2022).
8. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 5: management of tuberculosis in children and adolescents. Genebra: World Health Organization, https:// iris.who.int/bitstream/handle/10665/352522/9789240046764 eng.pdf?sequence=1 (2022).
9. Taneja R, Garcia-Prats AJ, Furin J, Maheshwari HK. Paediatric formulations of second-line anti-tuberculosis medications: challenges and considerations. Int J Tuberc Lung Dis. 2015; 19: 61–68. doi: 10.5588/ijtld.15.0435. PMID: 26564545.
10. Global Drug Facility. September 2023 Medicines Catalog. Genebra: Stop TB Partnership, 2023.
11. WHO-World Health Organization. The WHO Child Growth Standards, http://www.who.int/childgrowth/standards/ (2023).
12. Ministério da Saúde (BR) Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde. PORTARIA No 43, DE 6 DE SETEMBRO DE 2019, https://www.in.gov.br/web/dou/-/ portaria-n-43-de-6-de-setembro-de-2019-215084454 (2019).
13. Ministério da Saúde (BR) SVS. NOTA INFORMATIVA No 9/2021, https://www.gov.br/aids/pt-br/central-de-conteudo/notas informativas/2021/nota-informativa-no-9-2021-cgdr-dcci-svs ms/view (2021).